July 5, 2018
TOKYO, JAPAN - July 5, 2018 - Terumo Corporation (TSE: 4543) today announced that it has entered into an exclusive distribution relationship in Japan for a fentanyl injection anesthesia product with Piramal Critical Care Ltd., a wholly owned subsidiary of Piramal Enterprises Ltd., which is a diversified conglomerate headquartered in India. Piramal Critical Care acquired the product from Janssen Pharmaceutica NV in October 2016 and the product is currently marketed as a generic drug in Japan by Janssen Pharmaceutical K.K. With the conclusion of the exclusive distribution rights agreement, Terumo will take over marketing authorization of the product in Japan. The transfer of business is scheduled for the fiscal year 2019.
Fentanyl is a prescription-only narcotic analgesic that is widely used for postoperative pain management. Having designated pain management as an important business domain, Terumo also markets products that alleviate cancer pain and an intravenous injection of acetaminophen. With the conclusion of this exclusive distribution rights agreement, Terumo aims to expand treatment options to help alleviate patients' pain.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.